Skip to main content

Promis Neurosciences Inc(PMN-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low11.00
Day High11.50
Open:11.37
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
Newsfile
ProMIS Neurosciences Invited to Participate in the 2026 Bloom Burton & Co. Healthcare Investor Conference
GlobeNewswire
ProMIS Neurosciences Announces Full Year 2025 Financial Results and Provides Corporate Highlights
GlobeNewswire
ProMIS Neurosciences to Present Data on ALS & Parkinsons Disease Programs at Alzheimer’s Disease/Parkinson’s Disease 2026 International Conference (AD/PD™)
Tipranks
Guggenheim Remains a Buy on ProMIS Neurosciences (PMN)
GlobeNewswire
ProMIS Neurosciences to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
Tipranks
ProMIS Neurosciences Announces $75 Million PIPE Financing
GlobeNewswire
ProMIS Neurosciences Announces Up to $175 Million Private Placement Financing
Tipranks
ProMIS Neurosciences (PMN) Gets a Buy from Maxim Group
GlobeNewswire
ProMIS Neurosciences Exceeds Target Enrollment in PRECISE-AD Phase 1b Clinical Trial of PMN310 in Alzheimer’s Disease
Tipranks
ProMIS Neurosciences Regains Nasdaq Compliance
GlobeNewswire
ProMIS Neurosciences Announces New Peer-Reviewed Publication Highlighting Selective Targeting of Toxic Oligomers for Potential Clinical Benefit and Reduced ARIA Risk
GlobeNewswire
ProMIS Neurosciences Announces New Peer-Reviewed Publication Showing Plasma pTau as a Predictive Early Endpoint in Alzheimer’s trials, Supporting its Ongoing Phase 1b PRECISE-AD trial with PMN310
GlobeNewswire
ProMIS Neurosciences to Participate in the 8th Annual Evercore Healthcare Conference
Tipranks
Analysts Offer Insights on Healthcare Companies: ProMIS Neurosciences (PMN) and Crispr Therapeutics AG (CRSP)
Tipranks
ProMIS Neurosciences Announces Reverse Stock Split
GlobeNewswire
ProMIS Neurosciences Announces Reverse Stock Split
Tipranks
ProMIS Neurosciences Approves Key Shareholder Proposals
Tipranks
Analysts Offer Insights on Healthcare Companies: Butterfly Network (BFLY) and ProMIS Neurosciences (PMN)
Tipranks
ProMIS Neurosciences Reports Increased R&D Costs and Net Loss
Tipranks
ProMIS Neurosciences Appoints New Board Member
GlobeNewswire
ProMIS Neurosciences Strengthens Board with Appointment of Slanix Paul Alex, Pharm.D., President and Portfolio Manager, Public Equity of Ally Bridge Group
Tipranks
ProMIS Neurosciences Amends Employment Agreement with CSO
Newswire.ca
Anti-Aging Biotech Surges as $101M Competition Ignites Global Race Against Aging Demographics
Tipranks
ProMIS Neurosciences Advances Alzheimer’s Trial to Final Phase
GlobeNewswire
ProMIS Neurosciences Receives DSMB Approval to Advance to Final Dose Escalation Cohort in Phase 1b Alzheimer’s Trial of PMN310
Tipranks
ProMIS Neurosciences Announces At The Market Offering
Tipranks
ProMIS Neurosciences Reports Increased R&D Expenses and Net Loss
GlobeNewswire
ProMIS Neurosciences Announces Second Quarter 2025 Financial Results & Corporate Highlights
Tipranks
ProMIS Neurosciences Announces $3M PIPE Offering
GlobeNewswire
ProMIS Neurosciences to Showcase Protein-Misfolding Drug Discovery Platform & PRECISE-AD Trial Design at the 2025 Alzheimer’s Association International Conference
Tipranks
Analysts Are Bullish on Top Healthcare Stocks: ProMIS Neurosciences (PMN), Bruker (BRKR)
Tipranks
ProMIS Neurosciences Announces $3.2M Fundraising Initiatives

Profile

ProMIS Neurosciences Inc. is a development stage biotechnology company. It focused on discovering and developing medicine therapeutics to treat neurodegenerative diseases in particular Alzheimer's disease and amyotrophic lateral sclerosis. The company's product portfolio includes PMN310, PMN350, PMN330, PMN110, PMN120 and PMN130 which are in its pre-clinical stage. ProMIS Neurosciences Inc.is headquartered in Toronto, Canada.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2026 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.